Our Inhibitory Antibodies are research-grade biosimilar antibodies that have the same bioactive component as the original therapeutic antibodies. Biosimilar makes it possible to study the biological effects of a drug. These antibodies bind specifically to target cells or proteins, either stimulating the immune system to attack the malignant tumor cells or preventing tumor growth by blocking specific cell receptors. Target proteins include CD20, HER2, EGFR, VEGFR, TNF-alpha, etc. Our Inhibitory Antibodies have been extensively used in the most popular research fields, such as cancer, immunology and infection.